dalteparin has been researched along with Recrudescence in 200 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 36 (18.00) | 18.2507 |
| 2000's | 87 (43.50) | 29.6817 |
| 2010's | 66 (33.00) | 24.3611 |
| 2020's | 11 (5.50) | 2.80 |
| Authors | Studies |
|---|---|
| Brüggemann, R; Gietema, H; Jallah, B; Spaetgens, B; Stehouwer, C; Ten Cate, H | 1 |
| Amato, B; Buffone, G; de Franciscis, S; Molinari, V; Montemurro, R; Perri, P; Serra, R; Stillitano, DM | 1 |
| Eckstein, HH; Grau, C; Stammler, F | 1 |
| Alimi, YS; Hartung, O; Juhan, C; Miranda, E | 1 |
| Alhenc-Gelas, M; Corazza, F; Demulder, A; Ferster, A; Loop, M | 1 |
| Chang, CS; Chang, HW; Chang, WN; Chen, SD; Cheng, BC; Huang, CR; Hung, PL; Lin, TK; Lu, CH; Lui, CC; Tsai, NW; Wang, KW | 1 |
| Hu, CJ; Lai, CC | 1 |
| Kosior, DA; Opolski, G; Torbicki, A | 1 |
| Pistorius, MA; Planchon, B; Said, L | 1 |
| Krahe, T; Markert, T; Tschammler, A; Wittenberg, G | 1 |
| Barkagan, ZS | 1 |
| Brandjes, DP; Chesterman, CH; Gallus, AS; Koopman, MM; Ockelford, PA; Piovella, F; Prandoni, P; Prins, MH; Simonneau, G; van der Meer, J | 1 |
| Elikowski, W; Jazienicki, B; Lewandowski, K; Przybył, L; Przybył, M; Psuja, P; Wendland, M; Wróblewski, D; Zawilska, K | 1 |
| Hirsh, J | 1 |
| Bertrand, B; Bertrand, ME; d'Azemar, P; de Bruyne, B; Fontecave, S; Grentzinger, A; Grollier, G; Lablanche, JM; Legrand, V; Lusson, JR; Macaya, C; Masquet, C; McFadden, EP; Meneveau, N; Metzger, JP; Tobelem, G; Vacheron, A; Vahanian, A; Wolf, JE | 1 |
| Abufhele, A; Corbalán, R; Godoy, I; Herrera, C; Kunstmann, S; Zapata, C | 1 |
| Barsotti, A; Belcaro, G; Cesarone, MR; Christopoulos, D; Corsi, M; De Sanctis, MT; Incandela, L; Laurora, G; Lennox, A; Malouf, M; Nicolaides, AN; Vasdekis, S | 1 |
| Borja, J; Olivella, P | 1 |
| Ferrer, R; Grau, E; Medrano, J; Pastor, E; Real, E; Selfa, S; Tenias, JM | 1 |
| Horne, MK | 1 |
| Couturaud, F; Julian, JA; Kearon, C | 1 |
| Beyer, J; Schellong, SM; Schmidt, B; Schröder, HE; Schwarz, T | 1 |
| Avruscio, G; Bucherini, E; Campana, F; Camporese, G; Cosmi, B; Filippini, M; Ghirarduzzi, A; Imberti, D; Legnani, C; Palareti, G | 1 |
| Avruscio, G; Bucherini, E; Camporese, G; Cosmi, B; Filippini, M; Ghirarduzzi, A; Imberti, D; Palareti, G; Tonti, D | 1 |
| Anastasiadou, C; Galyfos, G; Geropapas, G; Giannakakis, S; Kastrisios, G; Kerasidis, S; Maltezos, C; Papacharalampous, G; Papapetrou, A; Sachmpazidis, I | 1 |
| Antonio, M; Domènech, P; Peñafiel, J; Peris, J; Pina, E; Rosselló, E; Tebe, C | 1 |
| Chen, N; Hamzeh, I; Kamran, H; Mims, M; Sudhakar, D | 1 |
| Chuzi, S; Eucalitto, P; Yee, LM | 1 |
| Johnson, SA; Jones, AE; Lai, N; Witt, DM | 1 |
| Levi, L; Sapir, E; Soudry, E; Yaniv, D; Zavdy, O | 1 |
| Bai, W; Fan, D; Guo, W; Han, G; Han, N; Li, K; Li, X; Luo, B; Lv, Y; Niu, J; Wang, E; Wang, J; Wang, Q; Wang, Z; Xia, D; Yin, Z; Yuan, J | 1 |
| Armstrong, PW; Gershlick, A; Halvorsen, S; Huber, K; Shavadia, J; Steg, PG; Van de Werf, F; Welsh, R; Zheng, Y | 1 |
| Amicucci, G; Clementi, M; Colozzi, S; Della Penna, A; Guadagni, S; Pessia, B; Schietroma, M; Sista, F | 1 |
| Alzghari, SK; Baty, KA; Evans, MF; Garza, JE; Hashimie, YF; Herrington, JD; Seago, SE; Shaver, C | 1 |
| An, SJ; Kim, CK; Kim, TJ; Ko, SB; Nam, KW; Oh, K; Yoon, BW | 1 |
| Gandhi, AS; Signorelli, JR | 1 |
| AlKhalfan, F; Cohen, AT; Daaboul, Y; Gibson, CM; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, RD; Kerneis, M; Korjian, S; Nafee, T; Wiest, C; Yee, MK | 1 |
| Kettle, JK; Ludwig, SL; Nicklaus, MD | 1 |
| Alva, H; Fletcher, M; Goyeneche, N; Warrier, R | 1 |
| Nowak, K; Pac, A; Stepien, K; Undas, A; Zalewski, J | 1 |
| Bott-Kitslaar, DM; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; Mcbane, RD; Peterson, LG; Vlazny, DT; Wysokinski, WE | 1 |
| Armstrong, PW; Arntz, HR; Bluhmki, E; Bogaerts, K; Carvalho, AC; Danays, T; Fresco, C; Gershlick, AH; Goldstein, P; Grajek, S; Halvorsen, S; Huber, K; Lambert, Y; Nanas, J; Ostojic, M; Regelin, A; Rosell Ortiz, F; Sulimov, V; Van de Werf, F; Vandenberghe, K; Welsh, RC; Wilcox, R | 1 |
| Camiolo, E; Carmina, MG; Fabbiano, F; Fiandaca, T; Indovina, A; Lucania, G; Malato, A; Marcenò, R; Messina, R | 1 |
| Ay, C; Hayde, M; Königsbrügge, O; Langer, M; Pabinger, I | 1 |
| Işik, B; Karakukcu, M; Mutlu, FT; Ozdemir, MA; Patiroglu, T; Unal, E; Yilmaz, E | 1 |
| Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM | 1 |
| Bookhart, B; Mody, SH; Ogden, K; Patel, AA | 1 |
| Gebel, M; Kooistra, HA; Lensing, AW; Meijer, K; Sahin, K | 1 |
| Cimbollek, S; Leguísamo, S; Piñero Saavedra, M; Prados Castaño, M | 1 |
| Agnelli, G; Buller, HR; Cohen, A; Gallus, AS; Lee, TC; Pak, R; Raskob, GE; Weitz, JI; Yamabe, T | 1 |
| Agnelli, G; Buller, HR; Cohen, AT; Gallus, AS; Ramacciotti, E; Raskob, GE; Sanders, P; Thompson, JR; Weitz, JI | 1 |
| Beyer-Westendorf, J; Bounameaux, H; Brighton, TA; Cohen, AT; Gebel, M; Lam, P; Lensing, AW; Levi, M; Martinelli, I; Middeldorp, S; Prins, MH; Trajanovic, M; van Bellen, B; Wells, PS | 1 |
| Beato, J; Carneiro, Â; Falcão, M; Fígueira, L; Penas, S; Reis, FF; Santos-Silva, R | 1 |
| Beyer-Westendorf, J; Bounameaux, H; Cohen, AT; Di Nisio, M; Fedacko, J; Fontes-Carvalho, R; Kubitza, D; Lensing, AW; Mueller, K; Pisters, R; Prandoni, P; Prins, MH; Riera-Mestre, A; Schneider, J; Vedovati, MC; Wells, PS | 1 |
| Bauersachs, RM; Beyer-Westendorf, J; Cheung, YW; Lensing, AW; Middeldorp, S; Milan, M; Pap, AF; Prandoni, P; Prins, MH; Ten Cate-Hoek, AJ; Verhamme, P; Villalta, S | 1 |
| Bomfim, GAZ; Cavalcante, RN; Centofanti, G; Fonseca, IYI; Krutman, M; Nishinari, K; Pignataro, BS; Ramacciotti, E; Sanches, SM; Teivelis, MP; Wolosker, N; Yazbek, G | 1 |
| Bascuñana, J; Bergmann, JF; Bortoluzzi, C; Ferrazzi, P; Giorgi-Pierfranceschi, M; López-Reyes, R; López-Sáez, JB; Monreal, M; Suriñach, JM; Trujillo-Santos, J | 1 |
| Brzosko, M; Przepiera-Będzak, H | 1 |
| Mantha, S; Miao, Y; Parameswaran, R; Soff, GA; Wills, J | 1 |
| Bohm, N; Duckett, A; Fisher, S; Tran, E | 1 |
| Castrodeza, J; González-Fajardo, JA; Martin-Pedrosa, M; Tamames, S; Vaquero-Puerta, C | 1 |
| Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH | 1 |
| DeYoung, P; Fitchett, DH; Goodman, SG; Huynh, T; Langer, A; Weeks, A; Yan, AT; Yan, RT | 1 |
| Giugliano, RP; Thomas, D | 1 |
| Becker, R; Benner, J; Deitelzweig, SB; Lin, J | 1 |
| Benchimol, C; Bresin, E; Bromberg, JS; Emre, SH; Magid, MS; Remuzzi, G; Saland, JM; Seikaly, MG; Shi, PA; Shneider, BL; Ward, SC | 1 |
| Bauer, T; Gitt, A; Heer, T; Jünger, C; Koeth, O; Senges, J; Zahn, R; Zeymer, U | 1 |
| Kremer, S; Kuntzmann, H; Laalou, FZ; Mahoudeau, G; Pain, L | 1 |
| Kehr, H; Love, BL; Olin, JL | 1 |
| Antman, EM; Braunwald, E; Gibson, CM; Giraldez, RR; Giugliano, RP; McCabe, CH; Mohanavelu, S; Morrow, DA; Murphy, SA | 1 |
| Bodian, M; Diack, B; Diao, M; Hakim, R; Kagambèga, LJ; Kane, A; Kane, M; Mbaye, A; Ndiaye, MB; Pessinaba, S; Sow, DD; Yaméogo, NV | 1 |
| Gans, RO; Landman, GW | 1 |
| Howard, L; Salooja, N | 1 |
| Aujesky, D; Beer, HJ; Cornuz, J; Egloff, M; Fine, MJ; Hugli, O; Legall, C; N'gako, A; Osterwalder, J; Perrier, A; Pugh, NA; Renaud, B; Righini, M; Roy, PM; Sanchez, O; Stone, RA; Verhamme, P; Verschuren, F; Yealy, DM | 1 |
| Balakhonova, TV; Dobrovol'skiĭ, AB; Ermolina, OV; Kirienko, AI; Panchenko, EP; Titaeva, EV; Vorob'eva, NM | 1 |
| Adnet, F; Aout, M; Bénezet, JF; Boulanger, B; Cayla, G; Chouihed, T; Cohen, M; Collet, JP; Combes, X; Ecollan, P; Elhadad, S; Filippi, E; Gallula, S; Goldstein, P; Greffet, A; Huber, K; Montalescot, G; Pollack, C; Silvain, J; Stibbe, O; Teiger, E; Vicaut, E; Zeymer, U | 1 |
| Agnelli, G; Berkowitz, SD; Bounameaux, H; Büller, HR; Chlumsky, J; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Jacobson, BF; Lensin, AW; Minar, E; Misselwitz, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P | 1 |
| Amitrano, L; Guardascione, MA; Lampasi, F; Lanza, AG; Manguso, F; Martino, R; Menchise, A; Scaglione, M | 1 |
| Altmeyer, P; Doerler, M; Reich-Schupke, S; Stücker, M | 1 |
| Alonso, A; Bigonzi, F; Goodman, S; Gosset, F; Kali, A; Krzemiñska-Pakula, M; Loos, U; Louer, V; Simoons, M | 1 |
| Albayrak, S; Atici, AG; Doru, F; Erkan, ML; Findik, S; Selçuk, MB | 1 |
| Fitchett, D; Goodman, SG; Gupta, M; Langer, A | 1 |
| Baloira Villar, A; Golpe Gómez, R; Pajuelo Fernández, F; Pérez de Llano, LA; Veiga, F; Veres Racamonde, A | 1 |
| Adamides, K; Goudevenos, J; Katsouras, CS; Michalis, LK; Naka, KK; Papamichael, N; Sideris, DA | 1 |
| Chan, AK; Goebel, G; Massicotte, MP; Streif, W | 1 |
| Armstrong, PW; Belmans, A; Dubois, CL; Fioretti, PM; Granger, CB; López-Sendón, JL; Meyer, J; Van de Werf, F; Verheugt, FW; Wallentin, L | 1 |
| Bigonzi, F; Cohen, M; Danchin, N; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L; White, HD | 1 |
| Bernink, PJ; Bijsterveld, NR; Cohen, M; Murphy, SA; Peters, RJ; Tijssen, JG | 1 |
| Büller, HR; Cariou, R; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Leeuwenkamp, O; Lensing, AW; Piovella, F; Prins, MH; Raskob, G; Segers, AE | 1 |
| Antman, EM; Braunwald, E; Chew, P; Fox, KA; Jiang, F; McCabe, CH; Morrow, DA; Sharma, D; White, HD | 1 |
| Armstrong, PW; Cowper, PA; Eisenstein, EL; Granger, CB; Kaul, P; Mark, DB; Van de Werf, F | 1 |
| Farkas, E; Köves, I; Mátrai, Z; Péley, G; Rényi-Vámos, F | 1 |
| Decousus, H; Derobert, E; Laporte, S; Levine, M; Merli, G; Mismetti, P; Quenet, S | 1 |
| Harenberg, J; Jörg, I; Weiss, C | 1 |
| Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Fox, KA; Granger, CB; Joyner, C; Mehta, SR; Peters, RJ; Pogue, J; Wallentin, L; Yusuf, S | 1 |
| Antman, EM; Braunwald, E; Budaj, A; Fox, KA; Guneri, S; Jiang, F; López-Sendón, JL; McCabe, CH; Morrow, DA; Murphy, SA; Ruda, M; Sadowski, Z; White, HD | 1 |
| Bischoff, A | 1 |
| Armstrong, PW; Bogaerts, K; Chang, WC; Danays, T; Goldstein, P; Granger, CB; Van de Werf, F; Wallentin, L | 1 |
| Boccadoro, M; Palumbo, A; Rodeghiero, F; Rus, C; Zeldis, JB | 1 |
| Alexander, JH; Harrington, RA | 1 |
| Jackson, WL; Moores, LK; Shorr, AF; Warkentin, TE | 1 |
| Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; Segers, AE | 1 |
| Antman, EM; Ardissino, D; Braunwald, E; Cohen, M; Gibson, CM; Gulba, DC; Kracoff, OH; Lewis, BS; Montalescot, G; Morrow, DA; Murphy, SA; Roguin, N | 1 |
| Bonomo, L; Cipriani, MC; Di Gennaro, L; Landolfi, R; Maggi, F; Novarese, L | 1 |
| Antman, EM; Bradner, JE; Gibson, CM; Giugliano, RP; Jang, IK; Morrow, DA; Qin, J; Scirica, B; Shui, A; Wiviott, SD; Yeh, RW | 1 |
| Almog, R; Justo, D; Kinori, M; Saar, N | 1 |
| Baglin, C; Baglin, T; Luddington, R; Palmer, CR | 1 |
| Aiello, S; Dettori, AG; Manotti, C; Pattacini, C; Pini, M; Poli, T; Quintavalla, R; Tagliaferri, A | 1 |
| Califf, R; Coté, G; Dorosti, K; Douglas, J; Faxon, DP; Gordon, JB; Gottlieb, R; Minor, S; Spiro, TE; Topol, E | 1 |
| Anderson, D; Demers, C; Gent, M; Ginsberg, J; Hirsh, J; Kovacs, M; Leclerc, J; Levine, M; Turpie, AG; Weitz, J | 1 |
| Glick, A; Keren, G; Koifman, B; Kornowski, R; Laniado, S; Michowich, Y; Roth, A | 1 |
| Force, RW | 1 |
| Bigonzi, F; Califf, RM; Cohen, M; Demers, C; Fox, KA; Fromell, GJ; Goodman, S; Gurfinkel, EP; Langer, A; Premmereur, J; Turpie, AG | 2 |
| Bentley, R; Bostwick, JS; Dunwiddie, CT; Kasiewski, CJ; Leadley, RJ; McVey, MJ; Perrone, MH; White, FJ | 1 |
| Barral, FG; Charbonnier, B; Decousus, H; Faivre, R; Girard, P; Huet, Y; Laporte, S; Leizorovicz, A; Page, Y; Parent, F; Simonneau, G; Tardy, B | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; McCabe, CH; Rifai, N; Sacks, DB | 1 |
| Bentley, R; Bostwick, JS; Dunwiddie, CT; Kasiewski, CJ; Leadley, RJ; Perrone, MH | 1 |
| Fox, KA | 1 |
| Armstrong, PW | 1 |
| Antman, EM; Bayes De Luna, A; Bernink, PJ; Braunwald, E; Fox, K; Gurfinkel, EP; Lablanche, JM; McCabe, CH; Premmereur, J; Radley, D; Salein, D; Turpie, AG | 1 |
| Ellis, MH; Manor, Y; Witz, M | 1 |
| Califf, RM; Cohen, M; Fox, KA; Fromell, GJ; Goodman, SG; Gurfinkel, EP; Stinnett, SS; Weatherley, BD | 1 |
| Barr, A; Cohen, M; Fromell, GJ; Goodman, SG; Hill, C; Langer, A; Laperrière, L; Sobtchouk, A | 1 |
| Bigonzi, F; Cohen, M; Danchin, N; Fox, KA; Gensini, GF; Gurfinkel, EP; Huber, K; Le-Louer, V; Maritz, F; Timerman, A; Vittori, L; White, H | 1 |
| Benzuly, K; Fintel, D; Nahlawi, M | 1 |
| Abildgaard, U; Davidson, BL; Eldor, A; Elias, D; Grigg, A; Merli, G; Musset, D; Olsson, CG; Rodgers, GM; Spiro, TE; Trowbridge, AA; Yusen, RD; Zawilska, K | 1 |
| Berto, P; Cimminiello, C; Kosa, J; Nadipelli, V; Nuijten, MJ; Spreafico, A | 1 |
| Baird, SH; Mcbride, SJ; Menown, IB; Trouton, TG; Wilson, C | 1 |
| Bounameaux, H; Sarasin, FP | 1 |
| Breddin, HK; Kadziola, Z; Kakkar, VV; Misselwitz, F; Nakov, R; Scully, M | 1 |
| Ahmed, RJ; Liu, L; Mehta, SR; Pais, P; Xavier, D; Xie, C; Yusuf, S; Zhu, J | 1 |
| de Bièvre, MA; de Jong, AE; Dijkstra, G; Hemker, HC; Oberndorff-Klein Woolthuis, AH; Schoon, EJ; Stockbrügger, RW; Vrij, AA | 1 |
| Karsch, KR; Preisack, MB | 1 |
| Baumbach, A; Herdeg, C; Jochims, K; Karsch, KR; Kranzhöfer, A; Oberhoff, M; Rübsamen, K; Safer, A | 1 |
| Baildon, R; Bonan, R; Eschenfelder, V; Foley, D; Garcia, EJ; Kaltenbach, M; Karsch, KR; Meisner, C; Preisack, MB; Selbmann, HK; Serruys, PW; Shiu, MF; Sujatta, M | 1 |
| Baildon, R; Büller, HR; Gallus, AS; Gent, M; Ginsberg, J; Prins, MH | 1 |
| Baildon, R; Bonan, R; Eschenfelder, V; Foley, D; Garcia, E; Kaltenbach, M; Karsch, KR; Meisner, C; Preisack, MB; Selbmann, HK; Serruys, PW; Shiu, MF; Sujatta, M | 1 |
| Boos, I; Göttman, D; Strecker, EP; Vetter, S | 1 |
| Breddin, HK; Fareed, J; Hoppenstead, DA; Kadziola, Z; Kakkar, VV; Nakov, R; Scully, M | 1 |
| Becker, LK; Harenberg, J; Melzer, N; Riess, H | 1 |
| Harenberg, J | 2 |
| Brom, J; Drexler, M; Gräve, M; Haas, S; Harenberg, J; Kemkes-Matthes, B; Koppenhagen, K; Patek, F; Riess, H; Siemens, HJ; Tolle, A; Weidinger, G | 1 |
| Büller, HR; Harenberg, J; Huisman, MV; Koppenhagen, K; Schmidt, JA; Tolle, A | 1 |
| Bewermeyer, H; Brom, J; Diener, HC; Gräve, M; Hennerici, M; Landgraf, H; Langohr, HD; Ringelstein, EB; von Kummer, R; Weidinger, G; Welzel, D | 1 |
| Breddin, HK; Harenberg, J; Huisman, MV; Kirchmaier, CM; Tolle, AR | 1 |
| Cho, YS; Gwak, HS; Han, JM; Kim, SH; Koh, Y; Lee, JH; Suh, SY; Yoon, JH; Yu, SJ | 1 |
| Ebner, M; Lankeit, M | 1 |
| Badgett, RG; Marshall, AL; Riaz, IB | 1 |
| Ashrani, A; Henkin, S; Le-Rademacher, JG; Lenz, CJ; Leon Ferre, RA; Loprinzi, CL; McBane Ii, R; Perez-Botero, J; Wysokinski, WE | 1 |
| Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, MA; Kakkar, AK; Kovacs, MJ; Mercuri, MF; Meyer, G; Raskob, GE; Segers, A; Shi, M; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Yeo, E; Zhang, G; Zwicker, JI | 1 |
| Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE | 1 |
| Carrier, M; Khorana, AA; Lee, AYY; Meyer, G; Noble, S; O'Connell, C; Soff, G | 1 |
| Beyer-Westendorf, J; Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, M; Hernandez, CR; Kakkar, AK; Kraaijpoel, N; Mercuri, MF; Middeldorp, S; Mulder, FI; Raskob, GE; Santamaria, A; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Zhang, G; Zwicker, JI | 1 |
| Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J | 1 |
| Hasegawa, K; Miyazaki, Y; Morimoto, T; Sase, K | 1 |
| Ragsdell, B; Thachil, J | 1 |
| Thachil, J | 2 |
| Gröschel, K; Hecking, C; Hendelmeier, M; Schinzel, H; von Bardeleben, R | 1 |
| Burr, S; Goldenberg, NA; Hamblin, F; Kulkarni, R; O'Brien, SH; Wallace, A | 1 |
| Gonzalez, CM; Madahar, P | 1 |
| Bergqvist, D; Francis, CW; Goldhaber, SZ; Huisman, MV; Kakkar, AK; Kessler, CM; Kovacs, MJ; Monreal, M; Ortel, TL; Pabinger, I; Spyropoulos, AC; Turpie, AG | 1 |
| Beyer-Westendorf, J; Bleker, SM; Boda, Z; Büller, HR; Carrier, M; Chlumsky, J; Décousus, H; Di Nisio, M; Garcia, D; Gibbs, H; Grosso, MA; Kakkar, A; Kamphuisen, PW; Mercuri, MF; Monreal, M; Ockelford, P; Pabinger, I; Raskob, GE; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Weitz, JI | 1 |
| Burgers, L; Dranitsaris, G; Shane, L; Woodruff, S | 1 |
| Debourdeau, P; Dranitsaris, G; Galanaud, JP; Shane, LG; Stemer, G; Woodruff, S | 1 |
| Bonet, M; Büller, H; Fraile, M; Lensing, AW; Monreal, M; Muchart, J; Roncales, J | 1 |
| Bergstrand, L; Dellborg, M; Fellenius, C; Granger, CB; Lindahl, B; Lins, LE; Nilsson, T; Pehrsson, K; Siegbahn, A; Swahn, E; Wallentin, L | 1 |
| Abbate, R; Fatini, C; Gensini, F; Gensini, GF; Marchionni, M; Mello, G; Parretti, E; Riviello, C; Scarselli, GF | 1 |
| Al-Yaseen, E; Anderson, J; Kovacs, MJ; Martin, J; Wells, PS | 1 |
| Battler, A; Chernine, A; Glikson, M; Hasdai, D; Kornowski, R; Ohad, D | 1 |
| del Rio, L; Lafoz, E; Monreal, M; Olive, A; Vedia, C | 1 |
| Baur, R; Dartsch, PC; Höher, M; Hombach, V; Osterhues, H; Seitzer, U; Voisard, R | 1 |
| Kher, A; Samama, MM | 1 |
| Cruickshank, M; Goudie, D; Kovacs, MJ; Morrow, B; Savage, KJ; Schulz, V; Wells, PS | 1 |
| Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM | 1 |
| Wallentin, L | 1 |
| Conen, D; Goede, J; Häfeli, R; Kraljevic, S; Wehrli, C | 1 |
| Bijsterveld, NR; Büller, HR; Levi, M; Meijers, JC; Moons, AH; Peters, RJ; Tijssen, JG | 1 |
| Bahlmann, F; Himmrich, L; Klotz, M; Peetz, D; Savvidis, S; Schinzel, H | 1 |
| Chatzis, D; Georgiadis, G; Giannoukas, AD; Ioannou, C; Kakkos, SK; Karathanos, C; Latzios, P; Vasdekis, S | 1 |
| Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G | 2 |
| André, M; Couturaud, F; Descourt, R; Leroyer, C; Meyer, G; Noel-Savina, E; Sanchez, O | 1 |
| Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AY; Meyer, G | 1 |
| Bonell, A; Cairols, MA; Colomé, E; Lapiedra, O; Martí, X; Romera, A; Vila-Coll, R | 1 |
| Brant, R; Cook, R; Hull, RD; Liang, J; Pineo, GF; Poon, MC; Raskob, G; Solymoss, S | 1 |
| Amraoui, S; Boulon, C; Conri, C; Constans, J; Solanilla, A; Viguier, JB | 1 |
| Bath, PM; Christensen, H; De Deyn, PP; England, T; Geeganage, C; Leys, D; Moulin, T; O'Neill, D; Ringelstein, EB; Sare, G; Tracy, M; Woimant, F | 1 |
| Daskalopoulos, ME; Daskalopoulou, SS; Dimitroulis, D; Kakissis, I; Liapis, CD; Nikolaou, A; Sfiridis, P; Tzortzis, E | 1 |
| Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K | 1 |
| Amathieu, R; Dhonneur, G; Fessenmeyer, C; Tual, L | 1 |
| Brant, RF; Burke, N; Cook, R; Dear, R; Hull, RD; Mah, AF; Pineo, GF; Poon, MC; Raskob, G; Solymoss, S; Wong, T | 1 |
| Azarian, R; Beau, B; Bosson, JL; Charbonnier, B; Ferrari, E; Hirsch, JL; Laaban, JP; Laurent, M; Mottier, D; Page, Y; Simonneau, G; Sors, H | 1 |
| Bell, D; Davenport, A; Fegan, C; Grech, H; Green, ES; O'Shaughnessy, D; Rose, P; Voke, J | 1 |
14 review(s) available for dalteparin and Recrudescence
| Article | Year |
|---|---|
[Per and early postoperative use of low molecular weight heparin in carotid surgery].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Vessel Prosthesis Implantation; Brain Ischemia; Carotid Artery Thrombosis; Carotid Stenosis; Constriction; Drug Evaluation; Endarterectomy, Carotid; Female; Humans; Male; Middle Aged; Nadroparin; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Complications; Premedication; Recurrence; Retrospective Studies; Treatment Outcome; Ultrasonography | 2003 |
[Recurrent pulmonary embolism in the functional loss of an LGM cava filter after the recanalization of a caval thrombosis].
Topics: Aged; Combined Modality Therapy; Equipment Failure; Femoral Vein; Heparin; Humans; Iliac Vein; Male; Nadroparin; Pulmonary Embolism; Radiography; Recurrence; Thrombosis; Vena Cava Filters; Vena Cava, Inferior | 1994 |
Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.
Topics: Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Incidence; Infusions, Intravenous; Injections, Subcutaneous; Nadroparin; Partial Thromboplastin Time; Randomized Controlled Trials as Topic; Recurrence; Safety; Thromboembolism; Thrombolytic Therapy; Thrombophlebitis; Warfarin | 1996 |
[Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Confidence Intervals; Dalteparin; Data Interpretation, Statistical; Double-Blind Method; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Myocardial Infarction; Nadroparin; Odds Ratio; Placebos; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Risk; Time Factors | 2000 |
Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Topics: Acute Disease; Anticoagulants; Dalteparin; Drug Administration Schedule; Enoxaparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Nadroparin; Odds Ratio; Pulmonary Embolism; Randomized Controlled Trials as Topic; Recurrence; Survival Analysis; Thromboembolism; Treatment Outcome; Venous Thrombosis | 2001 |
Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes.
Topics: Acute Disease; Algorithms; Clopidogrel; Coronary Disease; Coronary Thrombosis; Enoxaparin; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Risk Factors; Ticlopidine | 2002 |
Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Randomized Controlled Trials as Topic; Recurrence; Reproducibility of Results; Risk; Thromboembolism; Venous Thrombosis | 2005 |
Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data.
Topics: Area Under Curve; Drug Therapy, Combination; Emergency Treatment; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Intracranial Hemorrhages; Logistic Models; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Tenecteplase; Thrombolytic Therapy; Tissue Plasminogen Activator | 2006 |
Cost-effectiveness of enoxaparin as thromboprophylaxis in acutelly ill medical patients from the Italian NHS perspective.
Topics: Acute Disease; Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Humans; Recurrence; Thromboembolism | 2002 |
Fixed-dose versus adjusted-dose low molecular weight heparin for the initial treatment of patients with deep venous thrombosis.
Topics: Anticoagulants; Fibrin Fibrinogen Degradation Products; Heparin, Low-Molecular-Weight; Humans; Injections, Subcutaneous; Recurrence; Treatment Outcome; Venous Thrombosis | 2002 |
[Treatment of thrombosis with low-molecular-weight heparin. Comparison of body weight-adjusted and fixed dosage].
Topics: Adult; Aged; Anticoagulants; Data Interpretation, Statistical; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Multicenter Studies as Topic; Phlebography; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Risk; Thromboembolism; Thrombophlebitis; Time Factors; Treatment Outcome | 2003 |
Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.
Topics: Anticoagulants; Dalteparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Polysaccharides; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention; Tinzaparin; Venous Thromboembolism | 2018 |
[Low molecular weight heparin in unstable angina].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Survival Rate; Treatment Outcome | 1996 |
Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
Topics: Algorithms; Angina, Unstable; Anticoagulants; Biomarkers; Combined Modality Therapy; Coronary Angiography; Dalteparin; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Myocardial Revascularization; Postoperative Complications; Preoperative Care; Recurrence; Research Design; Risk Factors; Scandinavian and Nordic Countries; Time Factors; Treatment Outcome; Troponin T | 2000 |
91 trial(s) available for dalteparin and Recrudescence
| Article | Year |
|---|---|
Low molecular weight heparin improves healing of chronic venous ulcers especially in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Chronic Disease; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nadroparin; Recurrence; Treatment Outcome; Varicose Ulcer; Wound Healing | 2015 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, Intravenous; Injections, Subcutaneous; Length of Stay; Male; Middle Aged; Nadroparin; Quality of Life; Recurrence; Self Administration; Thromboembolism; Thrombosis; Treatment Outcome | 1996 |
[Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up].
Topics: Adult; Aged; Aspirin; Echocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Nadroparin; Pilot Projects; Recurrence; Streptokinase; Survival Rate; Thrombolytic Therapy; Thrombosis; Ventricular Dysfunction, Left | 1996 |
Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coronary Disease; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Nadroparin; Prospective Studies; Recurrence; Treatment Outcome | 1997 |
[Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina].
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Female; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Nadroparin; Recurrence | 1998 |
Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
Topics: Ambulatory Care; Anticoagulants; Female; Fibrinolytic Agents; Follow-Up Studies; Health Care Costs; Hemorrhage; Heparin; Hospitalization; Humans; Injections, Intravenous; Injections, Subcutaneous; International Normalized Ratio; Length of Stay; Male; Middle Aged; Nadroparin; Pulmonary Embolism; Recurrence; Safety; Ultrasonography, Doppler, Color; Ultrasonography, Doppler, Duplex; Venous Thrombosis; Ventilation-Perfusion Ratio | 1999 |
Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum).
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Multivariate Analysis; Recurrence; Risk Factors; Treatment Outcome; Venous Thrombosis; Young Adult | 2014 |
A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum).
Topics: Aged; Analysis of Variance; Anticoagulants; Chi-Square Distribution; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Italy; Kaplan-Meier Estimate; Lower Extremity; Male; Prospective Studies; Pulmonary Embolism; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Venous Thrombosis | 2012 |
Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.
Topics: Adult; Aged; Benzamides; Enoxaparin; Female; Humans; Male; Middle Aged; Pyridines; Recurrence; Secondary Prevention; Treatment Outcome; Venous Thromboembolism | 2018 |
Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Propensity Score; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Survival Analysis; Treatment Outcome; Venous Thromboembolism | 2019 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heart Failure; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Tenecteplase; Thrombolytic Therapy; Ticlopidine; Time-to-Treatment; Tissue Plasminogen Activator | 2013 |
Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Neoplasms; Prognosis; Recurrence; Risk Factors; Thrombophilia; Treatment Outcome; Venous Thromboembolism; Vitamin K; Warfarin | 2015 |
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
Topics: Aged; Anticoagulants; Chi-Square Distribution; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Neoplasms; Odds Ratio; Pyrazoles; Pyridones; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2015 |
Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial.
Topics: Adult; Aged; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Recurrence; Risk; Treatment Outcome; Venous Thromboembolism; Warfarin | 2016 |
Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Enoxaparin; Female; Humans; Male; Middle Aged; Recurrence; Rivaroxaban; Venous Thromboembolism; Vitamin K; Young Adult | 2016 |
Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Postthrombotic Syndrome; Recurrence; Rivaroxaban; Survival Analysis; Treatment Outcome; Venous Thrombosis; Vitamin K | 2016 |
Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin.
Topics: Anticoagulants; Coumarins; Enoxaparin; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Postthrombotic Syndrome; Prospective Studies; Recurrence; Thromboembolism; Time Factors; Venous Thrombosis | 2008 |
Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Electrocardiography, Ambulatory; Enoxaparin; Eptifibatide; Female; Hemorrhage; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Prognosis; Recurrence; Risk Assessment | 2008 |
Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Topics: Aged; Cause of Death; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Recurrence; Shock, Cardiogenic; Treatment Outcome | 2010 |
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Resources; Hemorrhage; Hospitalization; Humans; Injections, Subcutaneous; Length of Stay; Male; Middle Aged; Outcome Assessment, Health Care; Patient Readmission; Patient Satisfaction; Pulmonary Embolism; Recurrence | 2011 |
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence | 2011 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans; International Normalized Ratio; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Pulmonary Embolism; Recurrence; Rivaroxaban; Thiophenes; Treatment Outcome; Vitamin K | 2012 |
Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study.
Topics: Adult; Aged; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Recurrence; Streptokinase; Thrombolytic Therapy; Treatment Outcome | 2002 |
Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Injections, Subcutaneous; Male; Middle Aged; Odds Ratio; Pulmonary Embolism; Radiography; Recurrence; Time Factors; Treatment Outcome | 2002 |
[Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism].
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Recurrence; Safety; Treatment Outcome | 2003 |
Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial.
Topics: Aged; Angina, Unstable; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Recurrence; Tinzaparin | 2003 |
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
Topics: Abciximab; Alberta; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Belgium; Drug Administration Schedule; Drug Therapy, Combination; Elective Surgical Procedures; Emergency Treatment; Enoxaparin; Female; Fibrinolytic Agents; Germany; Heparin; Humans; Immunoglobulin Fab Fragments; Italy; Male; Middle Aged; Myocardial Infarction; Netherlands; North Carolina; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Spain; Survival Analysis; Sweden; Tenecteplase; Tissue Plasminogen Activator; Treatment Outcome | 2003 |
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial
Topics: Administration, Oral; Aspirin; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Incidence; Injections, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Time Factors; Tirofiban; Tyrosine | 2003 |
Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave C
Topics: Anticoagulants; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Recurrence | 2003 |
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Kidney; Male; Middle Aged; Polysaccharides; Recurrence; Treatment Outcome; Venous Thrombosis; Vitamin K | 2004 |
Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
Topics: Administration, Oral; Anticoagulants; Arteries; Azetidines; Benzylamines; Drug Therapy, Combination; Enoxaparin; Follow-Up Studies; Germany; Hemorrhage; Humans; Incidence; International Normalized Ratio; Muscle, Skeletal; Prospective Studies; Recurrence; Retinal Vein Occlusion; Time Factors; Venous Thrombosis; Warfarin | 2006 |
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Fondaparinux; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Polysaccharides; Recurrence; Stroke; Survival Analysis; Treatment Outcome | 2006 |
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
Topics: Aged; Anticoagulants; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Recurrence; Risk; Treatment Outcome | 2006 |
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Fondaparinux; Hemorrhage; Heparin; Humans; Male; Middle Aged; Obesity; Polysaccharides; Recurrence; Thromboembolism; Treatment Outcome; Venous Thrombosis | 2007 |
Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Chemotherapy, Adjuvant; Contraindications; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence; Thrombolytic Therapy; Time Factors; Treatment Outcome | 2007 |
Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Comorbidity; Enoxaparin; Female; Heparin; Humans; Incidence; Male; Middle Aged; Recurrence; Thrombocytopenia | 2007 |
Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cause of Death; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Heparin; Humans; Male; Middle Aged; Plethysmography; Radiography; Recurrence; Thrombophlebitis; Treatment Outcome; Warfarin | 1994 |
Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial.
Topics: Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Angiography; Coronary Disease; Double-Blind Method; Enoxaparin; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Recurrence; Time Factors | 1994 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Popliteal Vein; Recurrence; Self Administration; Thromboembolism; Thrombosis; Treatment Outcome | 1996 |
Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence; Streptokinase; Thrombolytic Therapy | 1996 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Myocardial Infarction; Recurrence; Risk | 1997 |
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Pulmonary Embolism; Recurrence; Survival Analysis; Thrombophlebitis; Treatment Outcome; Vena Cava Filters | 1998 |
Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy.
Topics: Aged; Angina, Unstable; Biomarkers; Cause of Death; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Forecasting; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Point-of-Care Systems; Prognosis; Recurrence; Risk Factors; Survival Rate; Syndrome; Thrombolytic Therapy; Time Factors; Troponin; Troponin T | 1998 |
Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Double-Blind Method; Drug Administration Routes; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Follow-Up Studies; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Safety; Survival Rate; Treatment Outcome | 1998 |
Low molecular weight heparin (enoxaparin) in the management of unstable angina: the ESSENCE study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events.
Topics: Adult; Aged; Angina, Unstable; Anticoagulants; Disease-Free Survival; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Recurrence | 1999 |
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Creatine Kinase; Double-Blind Method; Electrocardiography; Emergencies; Enoxaparin; Europe; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Isoenzymes; Life Tables; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; North America; Partial Thromboplastin Time; Recurrence; Safety; South America; Thrombolytic Therapy; Treatment Outcome | 1999 |
Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy.
Topics: Aged; Angina, Unstable; Aspirin; Drug Administration Routes; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Ischemia; Prognosis; Recurrence; Severity of Illness Index; Survival Rate | 2000 |
Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy.
Topics: Aged; Angina, Unstable; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Recurrence; Survival Rate; Time Factors | 2000 |
The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design.
Topics: Adult; Aged; Clinical Protocols; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Injections, Subcutaneous; Male; Middle Aged; Myocardial Infarction; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Survival Rate; Tirofiban; Tyrosine | 2000 |
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Infusions, Intravenous; Male; Middle Aged; Pulmonary Embolism; Recurrence; Risk Factors; Single-Blind Method; Thrombocytopenia; Treatment Outcome; Venous Thrombosis | 2001 |
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Injections; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Survival Analysis; Tenecteplase; Tissue Plasminogen Activator; Treatment Outcome | 2001 |
Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.
Topics: Aged; Anticoagulants; Endpoint Determination; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Heparin; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Recurrence; Risk Factors; Thrombolytic Therapy; Treatment Outcome | 2002 |
Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Topics: Ambulatory Care; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Cost-Benefit Analysis; Dalteparin; Decision Support Techniques; Drug Costs; Elective Surgical Procedures; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Humans; Markov Chains; Models, Theoretical; Postoperative Complications; Postoperative Period; Recurrence; Thrombosis; Warfarin | 2002 |
Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Antithrombin III; Biomarkers; Drug Administration Schedule; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Heparin; Heparin, Low-Molecular-Weight; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Peptide Fragments; Peptide Hydrolases; Phlebography; Prothrombin; Recurrence; Risk Factors; Severity of Illness Index; Thrombophlebitis; Treatment Outcome | 2003 |
Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation.
Topics: Aged; Angina Pectoris, Variant; Anticoagulants; Bundle-Branch Block; Double-Blind Method; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence; Risk; Stroke; Time Factors | 2005 |
Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis.
Topics: Adult; Colitis, Ulcerative; Colonoscopy; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fibrinolytic Agents; Follow-Up Studies; Heparin, Low-Molecular-Weight; Humans; Injections, Subcutaneous; Male; Patient Satisfaction; Quality of Life; Recurrence; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2007 |
Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early A
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coronary Disease; Coronary Vessels; Double-Blind Method; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Muscle, Smooth, Vascular; Prospective Studies; Recurrence | 1996 |
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.
Topics: Anticoagulants; Death, Sudden; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Pulmonary Embolism; Recurrence; Thrombophlebitis; Treatment Outcome | 1997 |
[Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study].
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cell Division; Coronary Angiography; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Recurrence; Treatment Outcome; Tunica Intima | 1997 |
[Dose-dependent decrease of the rate of restenosis of stents in peripheral vessels with reviparin].
Topics: Aged; Angiography, Digital Subtraction; Anticoagulants; Arterial Occlusive Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Femoral Artery; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Popliteal Artery; Prospective Studies; Recurrence; Stents | 1999 |
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis.
Topics: Acute Disease; Anticoagulants; Biomarkers; Blood Coagulation Factors; Heparin; Heparin, Low-Molecular-Weight; Humans; Partial Thromboplastin Time; Prospective Studies; Pulmonary Embolism; Recurrence; Thrombin; Venous Thrombosis; Vitamin K | 2002 |
Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin.
Topics: Aged; Anticoagulants; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Injections, Intravenous; Injections, Subcutaneous; Logistic Models; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Recurrence; Survival Analysis; Treatment Outcome; Venous Thrombosis | 2014 |
Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
Topics: Aged; Body Weight; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Recurrence; Thrombocytopenia; Venous Thrombosis | 2003 |
Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Body Weight; Cohort Studies; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Phlebography; Popliteal Vein; Postoperative Complications; Recurrence; Treatment Outcome; Venous Thrombosis; Vitamin K | 2000 |
Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Follow-Up Studies; Germany; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Recurrence; Severity of Illness Index; Stroke; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
Topics: Aged; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Phlebography; Recurrence; Survival Rate; Treatment Outcome; Venous Thrombosis | 2001 |
Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
Topics: Anticoagulants; Canada; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Neoplasms; Pyrazoles; Pyridones; Recurrence; Risk Factors; Time Factors; Treatment Outcome; United States; Venous Thromboembolism | 2017 |
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms; Pyridines; Recurrence; Thiazoles; Venous Thromboembolism | 2018 |
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Topics: Aged; Anticoagulants; Clinical Decision-Making; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Patient Selection; Pyridines; Recurrence; Risk Assessment; Risk Factors; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism | 2018 |
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Topics: Aged; Blood Coagulation; Dalteparin; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Neoplasms; Prospective Studies; Pulmonary Embolism; Pyridines; Recurrence; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2019 |
Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism.
Topics: Acute Disease; Adolescent; Age Factors; Anticoagulants; Child; Child, Preschool; Dalteparin; Drug Administration Schedule; Female; Hemorrhage; Humans; Infant; Infant, Newborn; Injections, Subcutaneous; Male; Patient Safety; Pilot Projects; Prospective Studies; Recurrence; Risk Factors; Time Factors; Treatment Outcome; United States; Venous Thromboembolism | 2014 |
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
Topics: Aged; Anticoagulants; Canada; Dalteparin; Drug Administration Schedule; Europe; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Prospective Studies; Recurrence; Risk Factors; Time Factors; Treatment Outcome; United States; Venous Thromboembolism | 2015 |
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
Topics: Adult; Anticoagulants; Dalteparin; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Neoplasms; Prospective Studies; Pulmonary Embolism; Pyridines; Recurrence; Research Design; Sample Size; Thiazoles; Time Factors; Treatment Outcome; Venous Thrombosis | 2015 |
Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cost-Benefit Analysis; Dalteparin; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Recurrence; Renal Insufficiency; Venous Thromboembolism; Vitamin K; Young Adult | 2016 |
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
Topics: Abciximab; Administration, Cutaneous; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Flow Velocity; Chemotherapy, Adjuvant; Coronary Angiography; Dalteparin; Drug Therapy, Combination; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Recurrence; Tissue Plasminogen Activator; Treatment Outcome; Vascular Patency | 2003 |
Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women.
Topics: Adult; Anticoagulants; Birth Weight; Circadian Rhythm; Dalteparin; Diastole; Female; Fetal Growth Retardation; Genetic Predisposition to Disease; Heparin, Low-Molecular-Weight; Homozygote; Humans; Infant, Newborn; Peptidyl-Dipeptidase A; Placental Circulation; Pre-Eclampsia; Pregnancy; Pregnancy Outcome; Recurrence; Risk; Sequence Deletion; Systole; Treatment Outcome; Ultrasonography, Doppler, Color; Ultrasonography, Doppler, Pulsed; Ultrasonography, Prenatal; Uterus; Vascular Resistance | 2005 |
Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
Topics: Adult; Aged; Aged, 80 and over; Contraindications; Coumarins; Dalteparin; Female; Fractures, Spontaneous; Hemorrhage; Heparin; Humans; Injections, Subcutaneous; Male; Middle Aged; Patient Compliance; Pulmonary Embolism; Recurrence; Spinal Fractures; Thromboembolism | 1994 |
Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Dalteparin; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Exercise Test; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence | 1996 |
Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Dalteparin; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Injections, Subcutaneous; Male; Middle Aged; Norway; Recurrence; Stroke; Treatment Outcome | 2000 |
Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
Topics: Algorithms; Angina, Unstable; Anticoagulants; Biomarkers; Combined Modality Therapy; Coronary Angiography; Dalteparin; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Myocardial Revascularization; Postoperative Complications; Preoperative Care; Recurrence; Research Design; Risk Factors; Scandinavian and Nordic Countries; Time Factors; Treatment Outcome; Troponin T | 2000 |
[Low molecular weight heparin (dalteparin) in treatment of patients with thromboembolism incidents].
Topics: Aged; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heparin; Humans; Injections, Subcutaneous; Male; Middle Aged; Recurrence; Thromboembolism | 2001 |
Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin.
Topics: Angina, Unstable; Anticoagulants; Coronary Thrombosis; Dalteparin; Female; Fibrinolysis; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Recurrence; Thrombin; Time Factors; Withholding Treatment | 2002 |
Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Fibrinolytic Agents; Glomerular Filtration Rate; Hemorrhage; Humans; Incidence; Kidney; Kidney Diseases; Male; Middle Aged; Neoplasms; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Time Factors; Tinzaparin; Treatment Outcome; Venous Thromboembolism; Warfarin; Young Adult | 2018 |
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Male; Middle Aged; Neoplasms; Pulmonary Embolism; Recurrence; Survival Analysis; Tinzaparin; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2015 |
Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial.
Topics: Aged; Biomarkers; C-Reactive Protein; Factor VIII; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Neoplasms; P-Selectin; Predictive Value of Tests; Prospective Studies; Recurrence; Risk Factors; Thromboplastin; Time Factors; Tinzaparin; Venous Thromboembolism | 2017 |
A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis.
Topics: Acenocoumarol; Administration, Oral; Age Factors; Anticoagulants; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Injections, Subcutaneous; International Normalized Ratio; Male; Middle Aged; Neoplasms; Prospective Studies; Recurrence; Risk Factors; Tinzaparin; Ultrasonography, Doppler, Duplex; Venous Thrombosis | 2009 |
Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome.
Topics: Administration, Oral; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Home Care Services; Humans; Injections, Subcutaneous; Male; Middle Aged; Patient Satisfaction; Postthrombotic Syndrome; Recurrence; Tinzaparin; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2009 |
Relationship between baseline blood pressure parameters (including mean pressure, pulse pressure, and variability) and early outcome after stroke: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST).
Topics: Aged; Blood Pressure; Female; Heparin, Low-Molecular-Weight; Humans; Hypertension; Male; Recurrence; Stroke; Time Factors; Tinzaparin; Treatment Outcome | 2011 |
Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial.
Topics: Acenocoumarol; Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Follow-Up Studies; Heparin; Heparin, Low-Molecular-Weight; Humans; Infusions, Intravenous; Injections, Subcutaneous; Long-Term Care; Male; Middle Aged; Partial Thromboplastin Time; Pulmonary Embolism; Recurrence; Tinzaparin; Ultrasonography, Doppler, Duplex; Vascular Patency; Venous Thrombosis | 2005 |
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms.
Topics: Anticoagulants; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Recurrence; Self Administration; Tinzaparin; Treatment Outcome; Venous Thrombosis; Vitamin K; Warfarin | 2007 |
A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.
Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Pulmonary Embolism; Radionuclide Imaging; Recurrence; Thromboembolism; Tinzaparin; Treatment Outcome | 1997 |
96 other study(ies) available for dalteparin and Recrudescence
| Article | Year |
|---|---|
Arterial and venous thromboembolic disease in a patient with COVID-19: A case report.
Topics: Anticoagulants; Cerebral Infarction; Clopidogrel; Computed Tomography Angiography; Coronavirus Infections; COVID-19; Frontal Lobe; Humans; Male; Middle Aged; Nadroparin; Pandemics; Peripheral Arterial Disease; Pneumonia, Viral; Pulmonary Embolism; Recombinant Proteins; Recurrence; Thrombophilia; Tinzaparin; Tissue Plasminogen Activator | 2020 |
[Digital ischemia in a gardener: is rose cutting a vascular risk factor?].
Topics: Alprostadil; Aneurysm; Anticoagulants; Aspirin; Diagnosis, Differential; Female; Finger Injuries; Fingers; Gardening; Hobbies; Humans; Ischemia; Magnetic Resonance Angiography; Middle Aged; Nadroparin; Photoplethysmography; Platelet Aggregation Inhibitors; Pulse; Radial Artery; Recurrence; Risk Factors; Treatment Outcome; Ultrasonography, Doppler, Color; Vasodilator Agents | 2008 |
Late onset of clinical symptoms and recurrent ecchymotic skin lesions in a 12-year-old girl with a severe double heterozygous protein C deficiency.
Topics: Age of Onset; Anticoagulants; Child; Coumarins; DNA Mutational Analysis; Ecchymosis; Family Health; Female; Heterozygote; Humans; Mutation, Missense; Nadroparin; Necrosis; Protein C Deficiency; Recurrence; Skin Diseases | 2004 |
Prognostic factors and therapeutic outcome of isolated symptomatic middle cerebral artery stenosis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Constriction, Pathologic; Female; Humans; Infarction, Middle Cerebral Artery; Magnetic Resonance Angiography; Male; Middle Aged; Middle Cerebral Artery; Nadroparin; Platelet Aggregation Inhibitors; Prognosis; Recurrence; Retrospective Studies; Treatment Outcome; Ultrasonography, Doppler, Transcranial; Warfarin | 2005 |
A left MCA territory infarction during intravenous recombinant tissue plasminogen activator therapy for right MCA territory ischaemic stroke.
Topics: Aged, 80 and over; Anticoagulants; Fibrinolytic Agents; Hospitalization; Humans; Infarction, Middle Cerebral Artery; Infusions, Intravenous; Magnetic Resonance Angiography; Male; Nadroparin; Recurrence; Tissue Plasminogen Activator; Tomography, X-Ray Computed | 2006 |
'Syringe-in-the-pocket'--a new approach to the outpatient thromboembolic prophylaxis of recurrent atrial fibrillation.
Topics: Aged; Ambulatory Care; Atrial Fibrillation; Electric Countershock; Feasibility Studies; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Nadroparin; Pilot Projects; Pulse; Recurrence; Self Administration; Thromboembolism | 2007 |
[Comparative study of the efficacy of a low dose of antivitamin K and a preventive dose of low molecular weight heparin in the prevention of relapses of deep venous thrombosis after curative treatment in the aged subject].
Topics: 4-Hydroxycoumarins; Aged; Anticoagulants; Dose-Response Relationship, Drug; Hemorrhage; Humans; Indenes; Nadroparin; Phenindione; Recurrence; Risk Factors; Thrombophlebitis; Vitamin K | 1994 |
[The use of fraxiparin for the prevention and treatment of thromboembolism in patients with heparin-induced thrombocytopenia].
Topics: Adult; Disseminated Intravascular Coagulation; Drug Evaluation; Female; Heparin; Humans; Male; Middle Aged; Nadroparin; Pregnancy; Pregnancy Complications, Hematologic; Recurrence; Thrombocytopenia; Thromboembolism | 1993 |
Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weight; Hospitalization; Humans; Incidence; Male; Middle Aged; Nadroparin; Recurrence; Retrospective Studies; Survival Rate; Thromboembolism; Venous Thrombosis | 2001 |
Secondary prophylaxis with low molecular weight heparin: the dose?
Topics: Acenocoumarol; Anticoagulants; Dose-Response Relationship, Drug; Drug Costs; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Nadroparin; Recurrence; Venous Thrombosis; Warfarin | 2001 |
Eligibility for home treatment of deep vein thrombosis: a prospective study in 202 consecutive patients.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Bandages; Combined Modality Therapy; Eligibility Determination; Female; Follow-Up Studies; Germany; Hemorrhage; Home Care Services; Hospitalization; Humans; Male; Middle Aged; Morbidity; Nadroparin; Outcome Assessment, Health Care; Patient Selection; Prospective Studies; Recurrence; Safety; Venous Thrombosis | 2001 |
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.
Topics: Adult; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arteritis; Aspirin; Cardiovascular Agents; Cilostazol; Critical Illness; Drug Therapy, Combination; Female; Heparin, Low-Molecular-Weight; Humans; Iloprost; Infusions, Intravenous; Ischemia; Limb Salvage; Lower Extremity; Male; Marijuana Abuse; Marijuana Smoking; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Smoking; Smoking Cessation; Tetrazoles; Thromboangiitis Obliterans; Time Factors; Treatment Outcome; Vasodilator Agents | 2017 |
Bemiparin as a long-term treatment for venous thrombosis in cancer patients: the ELEBAMA study.
Topics: Aged; Anticoagulants; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Recurrence; Venous Thromboembolism | 2020 |
A Sticky Situation: Aortic Valve Thrombus in Patient with Antiphospholipid Antibody Syndrome and Immune Thrombocytopenia.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aortic Valve; Aortic Valve Stenosis; Benzoates; Bicuspid Aortic Valve Disease; Bioprosthesis; Chest Pain; Craniotomy; Echocardiography; Echocardiography, Three-Dimensional; Echocardiography, Transesophageal; Enoxaparin; Female; Heart Valve Diseases; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hematoma, Subdural, Acute; Humans; Hydrazines; Immunologic Factors; Plasma Exchange; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Recurrence; Rituximab; Stroke Volume; Thrombosis; Ventricular Dysfunction, Left; Warfarin | 2020 |
A Pregnant Woman With Shortness of Breath.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Anticoagulants; Cesarean Section; Dyspnea; Echocardiography; Endocarditis; Enoxaparin; Female; Humans; Metoprolol; Mitral Valve Annuloplasty; Mitral Valve Insufficiency; Mitral Valve Stenosis; Postoperative Complications; Pregnancy; Pregnancy Complications, Cardiovascular; Recurrence; Reoperation; Severity of Illness Index | 2021 |
Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Male; Middle Aged; Neoplasms; Recurrence; Venous Thromboembolism | 2021 |
The Impact of Traditional Anticoagulants, Novel Anticoagulants, and Antiplatelets on Epistaxis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Enoxaparin; Epistaxis; Factor Xa Inhibitors; Female; Hospitalization; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Recurrence; Retrospective Studies; Safety; Severity of Illness Index; Warfarin | 2021 |
Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study.
Topics: Adult; Aged; Algorithms; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Male; Middle Aged; Mortality; Portal Vein; Portasystemic Shunt, Transjugular Intrahepatic; Prospective Studies; Recurrence; Rivaroxaban; Severity of Illness Index; Thrombosis; Warfarin; Watchful Waiting | 2021 |
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; Femoral Artery; Fibrinolytic Agents; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Mortality; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Radial Artery; Recurrence; Shock; ST Elevation Myocardial Infarction; Tenecteplase; Thrombolytic Therapy; Ticlopidine; Tissue Plasminogen Activator | 2016 |
Spontaneous liver rupture associated with anticoagulant therapy A case report.
Topics: Anticoagulants; Drug Therapy, Combination; Enoxaparin; Fatal Outcome; Hematoma; Hepatectomy; Humans; Liver Diseases; Pulmonary Embolism; Recurrence; Rupture, Spontaneous; Warfarin | 2017 |
Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasms; Pyrazoles; Pyridones; Recurrence; Retrospective Studies; Rivaroxaban; Secondary Prevention; Venous Thromboembolism; Warfarin | 2018 |
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Dabigatran; Dalteparin; Disability Evaluation; Enoxaparin; Female; Hemorrhage; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Recurrence; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Seoul; Stroke; Time Factors; Treatment Outcome | 2017 |
Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
Topics: Academic Medical Centers; Adult; Aged; Anticoagulants; Drug Substitution; Enoxaparin; Factor Xa Inhibitors; Female; Genital Neoplasms, Female; Hemorrhage; Humans; Middle Aged; Pilot Projects; Recurrence; Retrospective Studies; Rivaroxaban; Secondary Prevention; Venous Thromboembolism; Warfarin | 2019 |
Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Recurrence; Retrospective Studies; Rivaroxaban; Time Factors; Treatment Outcome; Venous Thromboembolism | 2018 |
Sports Injury or Venous Thrombosis?
Topics: Adolescent; Anticoagulants; Arm; Arthralgia; Athletic Injuries; Compression Bandages; Diagnosis, Differential; Edema; Enoxaparin; Heparin; Humans; Knee Joint; Magnetic Resonance Imaging; Male; May-Thurner Syndrome; Recurrence; Rivaroxaban; Subclavian Vein; Thrombectomy; Tomography, X-Ray Computed; Ultrasonography; Upper Extremity Deep Vein Thrombosis | 2019 |
Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabigatran; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2019 |
Multidisciplinary approach in pregnancy-associated thrombotic thrombocytopenic purpura: a case report.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Cesarean Section; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Infant, Newborn; Interdisciplinary Communication; Laryngeal Edema; Methylprednisolone; Patient Care Team; Plasma Exchange; Pregnancy; Pregnancy Complications, Hematologic; Puerperal Disorders; Pulmonary Embolism; Purpura, Thrombotic Thrombocytopenic; Recurrence; Rituximab; Warfarin | 2014 |
Oral anticoagulation with rivaroxaban during pregnancy: a case report.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Drug Substitution; Enoxaparin; Female; Humans; Infant, Newborn; Live Birth; Male; Morpholines; Pregnancy; Pregnancy Complications, Cardiovascular; Recurrence; Risk Factors; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Young Adult | 2014 |
A case of congenital afibrinogenemia complicated with thromboembolic events that required repeated amputations.
Topics: Afibrinogenemia; Amputation, Surgical; Anemia; Anticoagulants; Blood Coagulation Tests; Disease Progression; Enoxaparin; Female; Fibrinogen; Foot; Heparin; Humans; Ischemia; Necrosis; Recurrence; Toes; Young Adult | 2015 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment | 2015 |
The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
Topics: Anticoagulants; Computer Simulation; Cost-Benefit Analysis; Drug Therapy, Combination; Enoxaparin; Hemorrhage; Hospitalization; Humans; Models, Econometric; Pulmonary Embolism; Recurrence; Rivaroxaban; United States; Venous Thromboembolism; Vitamin K | 2015 |
Recurrent Anaphylaxis Due to Enoxaparin.
Topics: Anaphylaxis; Anticoagulants; Enoxaparin; Humans; Male; Middle Aged; Recurrence | 2015 |
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.
Topics: Adult; Anticoagulants; Contraceptives, Oral, Hormonal; Drug Synergism; Enoxaparin; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Progestins; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Rivaroxaban; Uterine Hemorrhage; Venous Thromboembolism; Young Adult | 2016 |
Presumed bilateral cilioretinal artery occlusion related to relapsing white dot syndrome.
Topics: Arterial Occlusive Diseases; Aspirin; Ciliary Arteries; Coloring Agents; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Fluorescein Angiography; Glucocorticoids; Humans; Indocyanine Green; Methylprednisolone; Papilledema; Recurrence; Retinal Artery Occlusion; Retinal Diseases; Tomography, Optical Coherence; Vision Disorders; Visual Acuity; Young Adult | 2016 |
Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Recurrence; Retrospective Studies; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Young Adult | 2017 |
Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism.
Topics: Acute Disease; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Europe; Female; Hemorrhage; Humans; Male; Middle Aged; Recurrence; Registries; Retrospective Studies; Risk Factors; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2017 |
Antiphospholipid Syndrome with Antiβ2glicoprotein-1 Antibodies as the Cause of Recurrent Tibial Vein Thrombosis in SAPHO syndrome.
Topics: Acquired Hyperostosis Syndrome; Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Enoxaparin; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Rare Diseases; Recurrence; Risk Assessment; Ultrasonography; Venous Thrombosis | 2016 |
Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Guideline Adherence; Hemorrhage; Humans; Male; Neoplasms; Platelet Count; Practice Guidelines as Topic; Quality Assurance, Health Care; Recurrence; Thrombocytopenia | 2017 |
Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment.
Topics: Administration, Oral; Anticoagulants; Cohort Studies; Enoxaparin; Female; Hemorrhage; Humans; Kidney; Liver; Male; Recurrence; Retrospective Studies; Venous Thromboembolism | 2017 |
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Dysfunction, Right | 2008 |
ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy.
Topics: Aged; Anticoagulants; Clopidogrel; Combined Modality Therapy; Comorbidity; Disease-Free Survival; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Stroke; Thrombolytic Therapy; Ticlopidine | 2009 |
Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
Topics: Anticoagulants; Cost-Benefit Analysis; Direct Service Costs; Drug Costs; Enoxaparin; Health Care Costs; Hemorrhage; Heparin; Hospital Costs; Humans; Insurance, Health, Reimbursement; Markov Chains; Models, Economic; Recurrence; Reproducibility of Results; Risk Assessment; Risk Factors; Treatment Outcome; Venous Thromboembolism | 2008 |
Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.
Topics: Anticoagulants; Child, Preschool; Complement Factor H; Enoxaparin; Hemolytic-Uremic Syndrome; Heterozygote; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Transplantation; Male; Mutation; Plasma Exchange; Recurrence; Treatment Outcome | 2009 |
Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Germany; Hemorrhage; Heparin; Hospital Mortality; Humans; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Registries; Retrospective Studies; Risk Assessment; Treatment Outcome | 2009 |
[Postoperative ischemic acute stroke and thrombolytic therapy].
Topics: Acute Disease; Aged; Anticoagulants; Aphasia, Broca; Aspirin; Cholesteatoma; Ear Diseases; Ear, External; Enoxaparin; Erythrocyte Transfusion; Female; Fibrinolytic Agents; Humans; Infarction, Middle Cerebral Artery; Lymph Node Excision; Magnetic Resonance Angiography; Postoperative Complications; Postoperative Hemorrhage; Recurrence; Thrombolytic Therapy; Tissue Plasminogen Activator | 2009 |
Hypertriglyceridaemia-induced acute pancreatitis due to patient non-compliance.
Topics: Acute Disease; Adult; Analgesics, Opioid; Enoxaparin; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Medication Adherence; Pancreatitis; Recurrence | 2009 |
[Pulmonary embolism mimicking acute anterior myocardial infarction: diagnostic trap].
Topics: Acenocoumarol; Acute Coronary Syndrome; Anterior Wall Myocardial Infarction; Anticoagulants; Coronary Angiography; Diagnostic Errors; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Humans; Middle Aged; Pulmonary Embolism; Recurrence; Signal Processing, Computer-Assisted; Streptokinase; Thrombolytic Therapy; Tomography, X-Ray Computed | 2011 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Recurrence; Risk Assessment; Rivaroxaban; Thiophenes; Venous Thrombosis | 2011 |
Outpatient management of pulmonary embolism.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Hospitalization; Humans; Injections, Subcutaneous; Patient Satisfaction; Pulmonary Embolism; Recurrence; Risk Factors; Venous Thromboembolism | 2011 |
[Improving recanalization of deep veins and the "outcomes" of venous thromboembolic complications in prolonged therapy with enoxaparin].
Topics: Adolescent; Adult; Aged; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Recurrence; Risk Factors; Russia; Thrombolytic Therapy; Time Factors; Ultrasonography, Doppler, Duplex; Venous Thromboembolism; Venous Thrombosis; Young Adult | 2010 |
Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis.
Topics: Aged; Anticoagulants; Chi-Square Distribution; Endoscopy, Gastrointestinal; Enoxaparin; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hemostatic Techniques; Humans; Kaplan-Meier Estimate; Ligation; Liver Cirrhosis; Male; Middle Aged; Recurrence; Secondary Prevention; Time Factors; Treatment Outcome; Ultrasonography, Doppler; Venous Thrombosis | 2012 |
Foam sclerotherapy with enoxaparin prophylaxis in high-risk patients with postthrombotic syndrome.
Topics: Anticoagulants; Combined Modality Therapy; Drug Administration Schedule; Enoxaparin; Humans; Polidocanol; Polyethylene Glycols; Postthrombotic Syndrome; Recurrence; Retrospective Studies; Risk Factors; Sclerotherapy; Thromboembolism; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Varicose Veins | 2013 |
Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients.
Topics: Anticoagulants; Antithrombin III; Catheters, Indwelling; Cohort Studies; Coronary Disease; Dose-Response Relationship, Drug; Enoxaparin; Female; Heart Defects, Congenital; Hemorrhage; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Prospective Studies; Recurrence; Thromboembolism; Treatment Outcome | 2003 |
Summaries for patients. Fondaparinux or enoxaparin for deep venous thrombosis?
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Kidney; Male; Middle Aged; Polysaccharides; Recurrence; Treatment Outcome; Venous Thrombosis; Vitamin K | 2004 |
Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thro
Topics: Double-Blind Method; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Research Design; Thrombolytic Therapy | 2005 |
Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiac Catheterization; Combined Modality Therapy; Coronary Artery Bypass; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Enoxaparin; Fees and Charges; Female; Health Resources; Heparin; Hospital Costs; Humans; Immunoglobulin Fab Fragments; Male; Medicare; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Postoperative Complications; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Survival Analysis; Tenecteplase; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome; United States | 2005 |
[Administration of clexane 4000 U/0.4 ml (40 mg) for preventing venous thromboembolic complications in patients undergoing surgery for malignant tumors. A follow-up study].
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Neoplasms; Recurrence; Thromboembolism | 2005 |
[Thromboembolisms endanger the internist patients, too: who needs heparin].
Topics: Age Factors; Aged; Anticoagulants; Dalteparin; Enoxaparin; Family Practice; Female; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Pregnancy; Pulmonary Embolism; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Thromboembolism; Time Factors; Venous Thrombosis | 2006 |
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxaparin; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Risk; Thalidomide; Thromboembolism; Time Factors | 2006 |
Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Humans; Intracranial Hemorrhages; Multicenter Studies as Topic; Myocardial Infarction; Polysaccharides; Recurrence; Risk; Treatment Outcome | 2006 |
Minimizing costs for treating deep vein thrombosis: the role for fondaparinux.
Topics: Body Weight; Costs and Cost Analysis; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Models, Economic; Polysaccharides; Recurrence; Thrombosis; Venous Thrombosis | 2007 |
Bilateral axillary vein thrombosis in a young patient with lupus anticoagulant and clavicular bone spurs.
Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Axillary Vein; Clavicle; Enoxaparin; Humans; Lupus Coagulation Inhibitor; Male; Osteophyte; Recurrence; Tomography, X-Ray Computed; Venous Thrombosis | 2007 |
Determination of anti-Xa levels in pregnant women treated with low molecular weight heparins for prevention of recurrent venous thromboembolism: a case report and review of the literature.
Topics: Adult; Disease Progression; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; Recurrence; Smoking; Venous Thromboembolism | 2008 |
Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Confounding Factors, Epidemiologic; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Contraindications; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Follow-Up Studies; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Recurrence; Risk Factors; Stockings, Compression; Thrombophlebitis; Venous Thrombosis | 2008 |
Home treatment of deep venous thrombosis.
Topics: Anticoagulants; Enoxaparin; Home Nursing; Humans; Injections, Intravenous; Randomized Controlled Trials as Topic; Recurrence; Thromboembolism; Treatment Outcome | 1996 |
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Topics: Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Collagen; Coronary Thrombosis; Dogs; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Hemostasis; Heparin; Hirudin Therapy; Hirudins; Male; Partial Thromboplastin Time; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Prothrombin; Prothrombin Time; Recombinant Proteins; Recurrence; Safety; Thrombin; Thrombolytic Therapy; Tissue Plasminogen Activator | 1997 |
Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin.
Topics: Animals; Anticoagulants; Coronary Thrombosis; Coronary Vessels; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa; Female; Hemodynamics; Heparin; Male; Partial Thromboplastin Time; Prothrombin; Prothrombin Time; Recurrence | 1998 |
Pursuing progress in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Hospitalization; Humans; Injections, Subcutaneous; Meta-Analysis as Topic; Myocardial Infarction; Recurrence; Thrombolytic Therapy; Treatment Outcome | 1999 |
Risk factors and management of patients with upper limb deep vein thrombosis.
Topics: Activated Protein C Resistance; Adult; Aged; Antithrombin III Deficiency; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Humans; Leg; Male; Middle Aged; Phlebography; Pregnancy; Prospective Studies; Protein S Deficiency; Recurrence; Retrospective Studies; Risk Factors; Streptokinase; Thrombolytic Therapy; Thrombophilia; Treatment Outcome; Ultrasonography, Doppler, Color; Venous Thrombosis; Warfarin | 2000 |
Concomitant use of eptifibatide and enoxaparin in the medical management of a patient with a non-ST segment elevation acute coronary syndrome and in-stent restenosis.
Topics: Adult; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Eptifibatide; Equipment Failure; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Myocardial Infarction; Myocardial Reperfusion; Peptides; Platelet Aggregation Inhibitors; Recurrence; Stents; Treatment Outcome | 2000 |
Low molecular weight heparin in prevention of restenosis after PTCA.
Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Coronary Angiography; Coronary Disease; DNA; DNA Replication; Dose-Response Relationship, Drug; Drug Administration Routes; Heparin, Low-Molecular-Weight; Humans; Muscle, Smooth, Vascular; Rabbits; Recurrence; Risk Factors | 1996 |
Porous balloon delivery of low molecular weight heparin in the dog coronary artery.
Topics: Angioplasty, Balloon, Coronary; Animals; Catheterization; Coronary Thrombosis; Coronary Vessels; Dogs; Drug Delivery Systems; Equipment Design; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Myocardium; Recurrence; Tunica Media | 1996 |
[Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
Topics: Anticoagulants; Body Weight; Clinical Trials as Topic; Fibrinolytic Agents; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Recurrence; Thrombophlebitis | 2003 |
Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients.
Topics: Anticoagulants; Dalteparin; Heparin, Low-Molecular-Weight; Humans; Liver Cirrhosis; Portal Vein; Recurrence; Retrospective Studies; Thrombosis; Venous Thrombosis | 2023 |
[Antithrombotic Treatment of Pulmonary Embolism].
Topics: Acute Disease; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fibrinolytic Agents; Fondaparinux; Guideline Adherence; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Long-Term Care; Neoplasms; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles | 2020 |
In cancer-associated VTE, apixaban was noninferior to dalteparin for recurrence and did not increase major bleeding.
Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Pyrazoles; Pyridones; Recurrence; Venous Thromboembolism | 2020 |
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; Hemorrhage; Humans; Multicenter Studies as Topic; Neoplasms; Observational Studies as Topic; Patient Acceptance of Health Care; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
VTE and anti-coagulation therapy in cancer patients.
Topics: Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Dalteparin; Factor Xa Inhibitors; Humans; Neoplasms; Pyridines; Recurrence; Risk Factors; Secondary Prevention; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2019 |
Lessons from recurrent deep vein thrombosis in Glanzmann thrombasthenia.
Topics: Aged; Dalteparin; Female; Fibrinolytic Agents; Humans; Platelet Membrane Glycoprotein IIb; Recurrence; Thrombasthenia; Tomography, X-Ray Computed; Ultrasonography; Venous Thrombosis | 2013 |
Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
Topics: Adult; Anticoagulants; Dalteparin; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Injections, Subcutaneous; Male; Middle Aged; Polysaccharides; Recurrence; Thrombocytopenia; Venous Thromboembolism; Warfarin | 2014 |
Recurrent cerebral ischaemia in a pregnant woman with patent foramen ovale II° and thrombophilia.
Topics: Adult; Anticoagulants; Brain Ischemia; Dalteparin; Female; Foramen Ovale, Patent; Humans; Injections, Subcutaneous; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Complications, Hematologic; Recurrence; Thrombophilia; Treatment Outcome | 2014 |
Heartache and bellyache: limited English proficiency perpetuating recurrent thromboembolic events.
Topics: Anticoagulants; Communication Barriers; Dalteparin; Female; Humans; Language; Medication Adherence; Middle Aged; Recurrence; Splenic Infarction; Thromboembolism; Thrombophilia | 2015 |
Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
Topics: Anticoagulants; Austria; Cost-Benefit Analysis; Dalteparin; Female; France; Humans; Male; Middle Aged; Neoplasms; Quality of Life; Recurrence; Venous Thromboembolism; Vitamin K | 2017 |
Should low molecular weight heparin dosing be based on anti-Xa assays in antiphospholipid syndrome?
Topics: Adult; Anti-Bacterial Agents; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Asymptomatic Diseases; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Factor Xa Inhibitors; Humans; International Normalized Ratio; Leg Ulcer; Lupus Coagulation Inhibitor; Male; Recurrence; Thrombophilia; Thrombophlebitis; Ultrasonography; Warfarin | 2013 |
Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study.
Topics: Anticoagulants; Cohort Studies; Dalteparin; Hemorrhage; Humans; Prospective Studies; Pulmonary Embolism; Recurrence; Safety; Venous Thrombosis; Vitamin K | 2002 |
The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Dalteparin; Female; Humans; International Normalized Ratio; Male; Medical Records; Middle Aged; Obesity; Recurrence; Retrospective Studies; Risk Factors; Thromboembolism; Time Factors; Venous Thrombosis; Warfarin | 2005 |
Low molecular weight heparin (Fragmin) prevents early reocclusion following femoral artery thrombolysis with rt-PA in rabbits.
Topics: Animals; Dalteparin; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Femoral Artery; Heparin; Rabbits; Random Allocation; Recurrence; Thrombolytic Therapy; Thrombosis; Tissue Plasminogen Activator | 1994 |
A prescreening system for potential antiproliferative agents: implications for local treatment strategies of postangioplasty restenosis.
Topics: Actins; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Arteriosclerosis; Cell Division; Cells, Cultured; Colchicine; Cyclosporine; Dalteparin; Doxorubicin; Drug Evaluation, Preclinical; Etoposide; Female; Femoral Artery; Fibrinolytic Agents; Gout Suppressants; Humans; Immunosuppressive Agents; Male; Microtubules; Middle Aged; Muscle, Smooth, Vascular; Recurrence; Vimentin | 1995 |
Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Arm; Catheterization, Central Venous; Cohort Studies; Dalteparin; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Prospective Studies; Pulmonary Embolism; Recurrence; Safety; Self Administration; Venous Thrombosis | 1999 |
[Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy].
Topics: Adolescent; Adult; Antithrombin III; Dalteparin; Dose-Response Relationship, Drug; Female; Fibrin Fibrinogen Degradation Products; Humans; Infant, Newborn; Injections, Subcutaneous; Peptide Hydrolases; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy, High-Risk; Recurrence; Self Administration; Thromboembolism | 2002 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Recurrence; Risk Factors; Tinzaparin; Venous Thromboembolism; Venous Thrombosis | 2023 |
Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Topics: Anticoagulants; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Neoplasm Metastasis; Neoplasms; Recurrence; Retrospective Studies; Risk Factors; Tinzaparin; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2015 |
[An image of vena cava thrombosis].
Topics: Adenocarcinoma, Clear Cell; Aged, 80 and over; Angiogenesis Inhibitors; Fibrinolytic Agents; Heart Atria; Heparin, Low-Molecular-Weight; Humans; Image Processing, Computer-Assisted; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Nephrectomy; Postoperative Complications; Pyrroles; Recurrence; Sunitinib; Thrombectomy; Tinzaparin; Tomography, X-Ray Computed; Vena Cava, Inferior; Venous Thrombosis | 2009 |
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Iliac Artery; Iloprost; Leg; Platelet Aggregation Inhibitors; Popliteal Artery; Radiography; Recurrence; Syndrome; Thrombocytopenia; Thrombosis; Ticlopidine; Tinzaparin | 2006 |
[Docetaxel-induced acute pulmonary capillary-leak syndrome mimicking cardiogenic oedema].
Topics: Acute Disease; Anticoagulants; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capillary Leak Syndrome; Diagnosis, Differential; Docetaxel; Dose-Response Relationship, Drug; Edema, Cardiac; Female; Heparin, Low-Molecular-Weight; Humans; Lung Neoplasms; Methylprednisolone; Middle Aged; Pulmonary Edema; Pulmonary Embolism; Recurrence; Respiration, Artificial; Spinal Neoplasms; Taxoids; Tinzaparin | 2007 |
The outcome of ambulatory DVT management using a multidisciplinary approach.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Disease Management; Drug Evaluation; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Hospitalization; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Survival Rate; Thromboembolism; Tinzaparin; Treatment Outcome; Venous Thrombosis | 2001 |